Formycon has recently seen positive uptake trends for its FYB201 biosimilar rival to Lucentis (ranibizumab) in both the US and UK, according to the latest figures revealed by the German developer.
Coherus And Formycon’s Ranibizumab Rapidly Ramps Up In US
Cimerli Biosimilar To Lucentis Captures 38% Of Total Market Volume In December 2023
Formycon has reported positive uptake trends in the US for its Coherus-partnered ranibizumab biosimilar at the end of 2023, mirroring recent success in the UK with marketing ally Teva.
